BALAXI PHARMACEUTICALS LIMITED Cash Flow Conversion Efficiency

Latest as of September 2025: 0.063x

BALAXI PHARMACEUTICALS LIMITED cash flow conversion efficiency. Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has a cash flow conversion efficiency ratio of 0.063x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs149.66 Million ≈ $1.62 Million USD) by net assets (Rs2.38 Billion ≈ $25.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of BALAXI PHARMACEUTICALS LIMITED (2013–2026)

Cash flow conversion efficiency of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2026. This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BALAXI stock price for real-time trading data and today's change.

BALAXI PHARMACEUTICALS LIMITED Cash Flow Conversion Ratio Explained

BALAXI PHARMACEUTICALS LIMITED cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

BALAXI PHARMACEUTICALS LIMITED Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their cash flow conversion efficiency. Also see BALAXI market cap overview for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Prochem S.A. WAR:PRM	0.055x
Prg Holdings Bhd KLSE:7168	-0.011x
Observe Medical Asa OL:OBSRV	-0.829x
Rayong Wire Industries Public Company Limited BK:RWI	-0.006x
GreenPro Capital Corp NASDAQ:GRNQ	-0.061x
Rougier S.A. PA:ALRGR	0.170x
Raspberry Pi Holdings PLC LSE:RPI	0.028x
Volex Plc LSE:VLX	0.107x

Annual Cash Flow Conversion Efficiency for BALAXI PHARMACEUTICALS LIMITED (2013–2026)

The table below shows the annual cash flow conversion efficiency of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2026. Review BALAXI PHARMACEUTICALS LIMITED (BALAXI) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	Rs2.49 Billion ≈ $26.94 Million	Rs-82.44 Million ≈ $-891.57K	-0.033x	+79.70%
2025-03-31	Rs2.32 Billion ≈ $25.06 Million	Rs-377.82 Million ≈ $-4.09 Million	-0.163x	-774.66%
2024-03-31	Rs2.01 Billion ≈ $21.78 Million	Rs48.66 Million ≈ $526.25K	0.024x	-27.26%
2023-03-31	Rs1.83 Billion ≈ $19.78 Million	Rs60.75 Million ≈ $657.02K	0.033x	-88.99%
2022-03-31	Rs1.13 Billion ≈ $12.24 Million	Rs341.44 Million ≈ $3.69 Million	0.302x	+632353.73%
2021-03-31	Rs649.80 Million ≈ $7.03 Million	Rs31.00K ≈ $335.25	0.000x	+100.01%
2020-03-31	Rs277.46 Million ≈ $3.00 Million	Rs-140.62 Million ≈ $-1.52 Million	-0.507x	-18.39%
2019-03-31	Rs35.21 Million ≈ $380.73K	Rs-15.07 Million ≈ $-162.98K	-0.428x	+1.89%
2018-03-31	Rs15.55 Million ≈ $168.13K	Rs-6.78 Million ≈ $-73.35K	-0.436x	-3.84%
2017-03-31	Rs23.59 Million ≈ $255.13K	Rs-9.91 Million ≈ $-107.20K	-0.420x	+88.57%
2016-03-31	Rs314.87K ≈ $3.41K	Rs-1.16 Million ≈ $-12.52K	-3.676x	-156.12%
2015-03-31	Rs322.45K ≈ $3.49K	Rs2.11 Million ≈ $22.84K	6.551x	+2233.63%
2014-03-31	Rs7.80 Million ≈ $84.33K	Rs-2.39 Million ≈ $-25.89K	-0.307x	-171.16%
2013-03-31	Rs7.52 Million ≈ $81.34K	Rs3.25 Million ≈ $35.09K	0.431x	--

About BALAXI PHARMACEUTICALS LIMITED

NSE:BALAXI India Drug Manufacturers - Specialty & Generic

Market Cap

$12.24 Million

Rs1.13 Billion INR

Market Cap Rank

#26387 Global

#1468 in India

Share Price

Rs20.50

Change (1 day)

+1.18%

52-Week Range

Rs15.67 - Rs42.26

All Time High

Rs207.74